Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of XGEVA in Chinese adults and skeletally mature adolescents with giant cell tumor of bone
CTR20231249Phase 4Active
- Sponsor
- Amgen
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Started Aug 2023; status: active.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on CTR20231249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231249.